Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.35 |
| ▸ | PTPRC | P08575 | 1/20 | 0.35 |
| ▸ | PTPRF | P10586 | 1/20 | 0.35 |
| ▸ | CDC25B | P30305 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | PTPN5 | P54829 | 2/20 | 0.31 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1505612 | 0.85 | PTGS2 (0.40) | PTGS2PTPN1PTPRCPTPRFCDC25B | |
| SCHEMBL1505749 | 0.84 | PTGS2 (0.39) | PTGS2PTPN1PTPRCPTPRFCDC25B | |
| SCHEMBL29644614 | 0.81 | PTPN1 (0.38) | PTGS2PTPN1PTPRCPTPRFCDC25B | |
| SCHEMBL30357793 | 0.75 | PTPN1 (0.34) | PTGS2PTPN1PTPRCPTPRFCDC25B | |
| SCHEMBL28420979 | 0.71 | POLB (0.36) | PTPN1PTPRCPTPRFCDC25B | |
| SCHEMBL30576990 | 0.71 | POLB (0.36) | PTPN1PTPRCPTPRFCDC25B | |
| SCHEMBL29073846 | 0.70 | PTGS2 (0.41) | PTGS2PTPN1PTPRCPTPRFCDC25B | |
| SCHEMBL5379529 | 0.69 | PTPN1 (0.35) | PTGS2PTPN1PTPRCPTPRFCDC25B | |
| SCHEMBL10713148 | 0.69 | HTR1A (0.38) | PTGS2PTPN1PTPRCPTPRFCDC25B | |
| SCHEMBL4476575 | 0.69 | PTGS2 (0.56) | PTGS2PTPN1PTPRCPTPRFCDC25B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108697713-A | Methods for making tricyclic PI3K inhibitor compounds and methods of treating cancer therewith | 基因泰克公司 | 2018-10-23 | — | — | CN | claimed |
| CN-106661039-B | 2 (TYK2) inhibitor of tyrosine protein matter kinases and its purposes | 林伯士拉克许米公司 | 2019-09-13 | — | — | CN | disclosed |
| CN-108779089-A | Griseofulvin compound | 第三共株式会社 | 2018-11-09 | — | — | CN | disclosed |
| CN-105492438-B | Sulfomimine substituted 5-fluoro-N- (pyridin-2-yl) pyridin-2-amine derivatives and their use as CDK9 kinase inhibitors | 拜耳医药股份有限公司 | 2018-08-07 | — | — | CN | disclosed |
| CN-105283453-B | N- (pyridin-2-yl) pyrimidin-4-amine derivatives containing sulfone group | 拜耳药业股份公司 | 2018-06-22 | — | — | CN | disclosed |
| CN-105073710-B | Novel hydroxamic acid derivative or salt thereof | 富山化学工业株式会社 | 2018-02-16 | — | — | CN | disclosed |
| CN-107001272-A | One-step method for synthesizing alkylated Metopirone analog | 阿尔比马尔公司 | 2017-08-01 | — | — | CN | disclosed |
| CN-106661039-A | TYK2 inhibitors and uses thereof | 林伯士拉克许米公司 | 2017-05-10 | — | — | CN | disclosed |
| CN-103649079-B | Hepatitis c inhibitor and application thereof | ABBVIE 公司 | 2016-11-16 | — | — | CN | disclosed |
| CN-105492438-A | Sulfomimine substituted 5-fluoro-N- (pyridin-2-yl) pyridin-2-amine derivatives and their use as CDK9 kinase inhibitors | Bayer Pharma AG | 2016-04-13 | — | — | CN | disclosed |
| CN-104540826-A | Spiro-fused piperidine derivatives useful as inhibitors of extrarenal potassium channels | MERCK SHARP & DOHME | 2015-04-22 | — | — | CN | disclosed |
| US-8957102-B2 | Heterocyclic compound as protein kinase inhibitor | NEOPHARM CO., LTD. (KR) | 2015-02-17 | — | — | US | disclosed |
| US-20120289509-A1 | HETEROCYCLIC COMPOUND AS PROTEIN KINASE INHIBITOR | NEOPHARM CO., LTD. (KR) | 2012-11-15 | — | — | US | disclosed |
| US-20110183983-A1 | HETEROCYCLIC COMPOUND AS PROTEIN KINASE INHIBITOR | NEOPHARM CO., LTD. (KR) | 2011-07-28 | — | — | US | disclosed |
| EP-2336123-A2 | HETEROCYCLIC COMPOUND AS PROTEIN KINASE INHIBITOR | Neopharm Co., Ltd. (KR) | 2011-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183983-A1 | HETEROCYCLIC COMPOUND AS PROTEIN KINASE INHIBITOR | MET, HGFAC, DMPK | PTGS2 1708/4885PTPN1 1095/4885PTPRC 527/4885 |
| US-20120289509-A1 | HETEROCYCLIC COMPOUND AS PROTEIN KINASE INHIBITOR | MET, HGFAC, DMPK | PTGS2 1708/4885PTPN1 1095/4885PTPRC 527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.